phosphoribosyl-n-formylglycineamide has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 1 studies
Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pemetrexed represents the first antifolate cancer drug to be approved by the Food and Drug Administration in 20 years; it is currently in widespread use for first line therapy of mesothelioma and non-small cell lung cancer." | 3.75 | Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. ( Heyer, CL; Moran, RG; Racanelli, AC; Rothbart, SB, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Racanelli, AC | 1 |
| Rothbart, SB | 1 |
| Heyer, CL | 1 |
| Moran, RG | 1 |
1 other study available for phosphoribosyl-n-formylglycineamide and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition.
Topics: Adenylate Kinase; Aminoimidazole Carboxamide; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; | 2009 |